The purpose of this study is to assess the efficacy and safety of oral propranolol versus nadolol in patients with Infantile Hemangiomas (IH) in a randomized, controlled, double-blinded study.

开始日期2015-09-01

申办/合作机构

The Hospital for Sick Children

100 项与纳多洛尔相关的临床结果

登录后查看更多信息

100 项与纳多洛尔相关的转化医学

登录后查看更多信息

100 项与纳多洛尔相关的专利（医药）

登录后查看更多信息

1,234

项与纳多洛尔相关的文献（医药）

2024-10-22·BIOLOGICAL & PHARMACEUTICAL BULLETIN

Evaluation of β-Blocker-Induced Bradyarrhythmia Using an Analysis of the Japanese Adverse Drug Event Report Database

Article

作者: Uesawa, Yoshihiro ; Motoishi, Hiroyuki ; Ishii-Nozawa, Reiko

β-Adrenergic receptor blockers (β-blockers) are used to treat hypertension, ischemic heart disease, chronic heart failure, and tachyarrhythmia. The main side effects of treatment include bradycardia, atrioventricular block, and hypotension. Bradycardia may result in pacemaker implantation as well as the discontinuation of β-blockers. Bradycardia is difficult to confirm at a single institution because it diagnosed only by symptoms when electrocardiogram (ECG) are not routinely performed. Previous studies reported an increase in bradycardia in heart failure patients treated with β-blockers; however, limited information is currently available for non-heart failure patients. Bradycardia induced by β-blockers has not yet been comprehensively examined. Therefore, the present study investigated data on the incidence and duration of bradyarrhythmia caused by β-blockers using the Japanese Adverse Drug Event Report database (JADER). Cases of adverse effects associated with this medication were extracted from JADER and Fisher's exact test was performed to assess whether each β-blocker caused bradyarrhythmia. In addition, only data from patients who reported bradyarrhythmia after β-blocker treatment were extracted, and the Weibull distribution was used to analyze the time-to-onset of bradyarrhythmia. Thirteen β-blockers caused bradyarrhythmia and signals were observed for 12 drugs, except nadolol. Bradyarrhythmia induced by oral β-blockers was more likely to be of the early failure type, and developed within 2 months of treatment initiation with most β-blockers. A comprehensive analysis of bradyarrhythmia with β-blockers suggests that careful monitoring is needed, particularly early in the initiation of treatment.

2024-10-01·MICROCHIMICA ACTA

Magnetic particle spray mass spectrometry for the determination of beta-blockers in plasma samples

Article

作者: Rosa, Mariana Azevedo ; Mendes, Tássia Venga ; Moreira, Ailton José ; de Castilho Alves Morais, Elizângela Maria ; Figueiredo, Eduardo Costa ; Gorup, Luiz Fernando ; Arnoni, Estela Domingos

Magnetic particle spray mass spectrometry (MPS-MS), an innovative ambient ionization technique proposed by our research group, was employed to determine beta-blockers in human plasma samples. A dispersive solid phase extraction of atenolol, metoprolol, labetalol, propranolol, nadolol, and pindolol was carried out using magnetic molecularly imprinted polymer (M-MIP) particles that were attached to the tip of a metal probe, which was placed in the mass spectrometer inlet. A solvent (1% formic acid in methanol) was dispensed on the particles, and the Taylor cone was formed around them (in high voltage). The analytes were desorbed/ionized and determined by a triple quadrupole mass spectrometer. M-MIP was synthesized with oxprenolol as a pseudo-template, demonstrating good selectivity to beta-blockers compared with no-analog molecules, with an adsorption process occurring in monolayers, according to isotherm studies. Kinetic experiments indicated chemisorption as the predominant M-MIP/analyte interaction. The analytical curves were linear (R² > 0.98), and the limit of quantification was 3 µg L^-1 for all the analytes. Limits of detection ranged from 0.64 to 2.41 µg L^-1. Precisions (relative standard deviation) and accuracies (relative error) ranged from 3.95 to 21.20% and -17.05 to 18.93%, respectively. MPS-MS proved to be a simple, sensitive, and advantageous technique compared with conventional approaches. The analyses were fast, requiring no chromatographic separation and without ionic suppression. The method is aligned with green chemistry principles, requiring minimal sample, solvent, and sorbent amounts. MPS-MS successfully integrates sample preparation and ambient ionization mass spectrometry and holds great potential for application with other sorbents, samples, and analytes.

2024-10-01·HEADACHE

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features

Article

作者: Chiang, Chia‐Chun ; Wang, Han ; Montenegro, Monique M. ; Burke, Krista M. ; Wang, Liguo ; Dumkrieger, Gina ; Whealy, Mark ; Ouellette, Heather A. ; Banerjee, Imon ; Jones, Brandon M. ; Chao, Chieh‐Ju ; Chen, Yi‐Chieh ; Murray, Ann M. ; Schwedt, Todd J. ; Stern, Jennifer I. ; Cutrer, Fred M. ; Kissoon, Narayan

Abstract:

Objective:

To develop machine learning models using patient and migraine features that can predict treatment responses to commonly used migraine preventive medications.

Background:

Currently, there is no accurate way to predict response to migraine preventive medications, and the standard trial‐and‐error approach is inefficient.

Methods:

In this cohort study, we analyzed data from the Mayo Clinic Headache database prospectively collected from 2001 to December 2023. Adult patients with migraine completed questionnaires during their initial headache consultation to record detailed clinical features and then at each follow‐up to track preventive medication changes and monthly headache days. We included patients treated with at least one of the following migraine preventive medications: topiramate, beta‐blockers (propranolol, metoprolol, atenolol, nadolol, timolol), tricyclic antidepressants (amitriptyline, nortriptyline), verapamil, gabapentin, onabotulinumtoxinA, and calcitonin gene‐related peptide (CGRP) monoclonal antibodies (mAbs) (erenumab, fremanezumab, galcanezumab, eptinezumab). We pre‐trained a deep neural network, “TabNet,” using 145 variables, then employed TabNet‐embedded data to construct prediction models for each medication to predict binary outcomes (responder vs. non‐responder). A treatment responder was defined as having at least a 30% reduction in monthly headache days from baseline. All model performances were evaluated, and metrics were reported in the held‐out test set (train 85%, test 15%). SHapley Additive exPlanations (SHAP) were conducted to determine variable importance.

Results:

Our final analysis included 4260 patients. The responder rate for each medication ranged from 28.7% to 34.9%, and the mean time to treatment outcome for each medication ranged from 151.3 to 209.5 days. The CGRP mAb prediction model achieved a high area under the receiver operating characteristics curve (AUC) of 0.825 (95% confidence interval [CI] 0.726, 0.920) and an accuracy of 0.80 (95% CI 0.70, 0.88). The AUCs of prediction models for beta‐blockers, tricyclic antidepressants, topiramate, verapamil, gabapentin, and onabotulinumtoxinA were: 0.664 (95% CI 0.579, 0.745), 0.611 (95% CI 0.562, 0.682), 0.605 (95% CI 0.520, 0.688), 0.673 (95% CI 0.569, 0.724), 0.628 (0.533, 0.661), and 0.581 (95% CI 0.550, 0.632), respectively. Baseline monthly headache days, age, body mass index (BMI), duration of migraine attacks, responses to previous medication trials, cranial autonomic symptoms, family history of headache, and migraine attack triggers were among the most important variables across all models. A variable could have different contributions; for example, lower BMI predicts responsiveness to CGRP mAbs and beta‐blockers, while higher BMI predicts responsiveness to onabotulinumtoxinA, topiramate, and gabapentin.

Conclusion:

We developed an accurate prediction model for CGRP mAbs treatment response, leveraging detailed migraine features gathered from a headache questionnaire before starting treatment. Employing the same methods, the model performances for other medications were less impressive, though similar to the machine learning models reported in the literature for other diseases. This may be due to CGRP mAbs being migraine‐specific. Incorporating medical comorbidities, genomic, and imaging factors might enhance the model performance. We demonstrated that migraine characteristics are important in predicting treatment responses and identified the most crucial predictors for each of the seven types of preventive medications. Our results suggest that precision migraine treatment is feasible.

项与纳多洛尔相关的新闻（医药）

2024-07-12

·生物谷

Heart Rhythm | 小心“功能饮料”，或成心脏“杀手”！5000人队列研究：能量饮料可致心律失常，尤其是这类人

白天上班犯困、晚上熬夜加班是很多工作党的常态，很多人为了保证精力会选择功能性饮料来补充能量。功能饮料，又称能量饮料，指的是那些通过调整饮料中各种营养素的成分和含量比例，能在一定程度上调节人体功能，不以治疗疾病为目的的饮料。近日，一项来自梅奥诊所的研究表明，对于患有某些遗传性心脏病的人来说，饮用功能饮料可能会带来心脏病发作的风险。功能饮料可能是“致心律失常的食物”，不仅含有大量咖啡因，还含有牛磺酸和瓜拉那等，可能对心脏健康产生不利影响的化合物。该研究题为“Sudden cardiac arrest occurring in temporal proximity to consumption of energy drinks”，发表在Heart Rhythm杂志。一、研究背景过去几年，美国的能量饮料市场持续增长。这些饮料大多声称含有天然成分，属于膳食补充剂而非药物，因此美国食品药品管理局 (FDA) 无需对这些产品或制造商进行监控。随着新兴品牌瞄准更年轻的年龄群体，能量饮料已成为青少年和年轻人中继复合维生素之后消费量第二大的补充剂。这些饮料每份含咖啡因80至300毫克，而一杯8盎司的煮咖啡仅含100毫克。然而，这些能量饮料中的大部分除了咖啡因外还含有其他不受FDA监管的刺激性成分，如牛磺酸和瓜拉那。先前的研究表明，高咖啡因摄入量（每天超过10杯咖啡）与心脏骤停 (SCA) 之间存在潜在相关性。患有遗传性心脏病 (GHD) 的人患心脏骤停和心源性猝死的风险增加，而能量饮料的流行度激增、每份饮料中咖啡因含量的增加以及几种不受管制的成分的存在引起了人们对GHD患者使用这些饮料的担忧。本研究旨在调查在患有潜在GHD的患者中，能量饮料的消费与心脏事件（特别是心脏骤停）风险之间是否存在潜在的时间关联。二、研究方法这项经梅奥诊所机构审查委员会批准的研究中，研究人员对2000年7月至2023年1月期间在梅奥诊所Windland Smith Rice遗传心律诊所接受评估的5000多名患者进行了回顾性审查，以确定在SCA中幸存下来的患者子集（N=144；51%为女性），这些患者被证实有心律失常，需要复苏和/或除颤。在 144 名 SCA 幸存者中，研究人员通过广泛的图表审查确定了在饮用能量饮料后不久经历了记录的先兆事件或突破性心脏事件 (BCE) 的患者子集。先兆事件定义为诊断前发生的事件，而BCE定义为诊断和开始治疗后发生的事件。研究人员对电子医疗记录进行了评估，以确定患者的人口统计学、临床特征、记录的能量饮料消费量以及能量饮料消费与SCA的时间关系。患者自我报告饮用能量饮料是频繁还是不频繁。三、研究结果在144名SCA幸存者中，7名患者的能量饮料摄入与SCA之间存在时间相关性。6 名患者在能量饮料摄入后发生SCA是警示事件，其余患者为BCE。在对这7名患者进行全面的临床评估后，3名被诊断为原因不明的SCA/IVF，2名患有CPVT，2名患有LQTS。 3 名患者报告称经常饮用能量饮料，而其余 4 名患者则很少饮用。饮用能量饮料与事件发生之间的时间间隔从 12 小时内到事件发生前不等。饮用的能量饮料类型各异，咖啡因含量从每份 80 毫克到 >200 毫克不等。大多数患者需要对恶性心律失常进行抢救性电击，而 1 名患者接受了胸外按压和心前区捶击等人工复苏。事件发生后，梅奥诊所进行了临床评估，7 名患者中有 6 名出院时植入了植入式心脏复律除颤器 (ICD)，2 名接受了左心交感神经切除术 (LCSD)，2 名出院时接受了药物治疗。其中一名患者没有改变她已经建立的纳多洛尔、氟卡尼和 LCSD 三重保护治疗，只是改变了她的习惯，戒掉了能量饮料和电子烟。在 SCA 之后，所有患者都停止饮用能量饮料，进一步进行风险分层，并优化了针对疾病的治疗。此后，他们一直没有 BCE，平均随访时间为 52 ± 43 个月。四、总结本文介绍了7例GHD患者，他们在饮用能量饮料后不久就发生了 SCA。在大多数病例中（4 [57%]），患者并不经常饮用高剂量的咖啡因。虽然饮用能量饮料和 SCA 事件之间似乎存在时间关系，但其中几起事件发生在无数潜在的“刺激因素”中，这些因素也可能导致与GHD相关的心律失常，例如睡眠不足、脱水、节食或极度禁食、同时使用 QT 延长药物或产后时期。因此，异常饮用咖啡因很可能与其他变量相结合，形成风险因素的“完美风暴”，导致这些患者出现SCA。总之，研究接受评估的个体中，5%的SCA幸存者在发病前饮用过一种或多种能量饮料。尽管发病率很低，但能量饮料可能会引发GHD患者的SCA，因此应尽早警告这些饮料对这些患者的潜在风险。应教育患者尽量减少能量饮料的摄入，敦促 FDA提供有关正确和安全使用这些饮料的指南。参考文献： https://www.heartrhythmjournal.com/article/S1547-5271(24)00189-9/fulltext#secsectitle0010d 撰写 | Catherine 编辑 | 小饼干来源 | 梅斯学术本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

临床研究

2024-07-08

·BiG生物创新社

诺和诺德高血压药物，OcedurenoneⅢ期临床失败

作者｜YY 在坐拥“法力无边”的GLP-1药物semaglutide的同时，诺和诺德也居安思危地扩展其商业领域。去年以13亿美元收购亨利医药（KBP Biosciences）的心/肾脏病控制高血压药物ocedurenone（图1），就代表着诺和诺德将业务扩展到代谢疾病以外的战略思想。 Ocedurenone的原本目标是成为同类最优的控制高血压治疗药物，然而近期风光无限的诺和诺德却在ocedurenone的Ⅲ期临床研究Clarion-CKD中遭遇失败。图1. Ocedurenone化学结构。 01 诺和诺德罕见临床失败诺和诺德日前表示，在研究了ocedurenone的临床数据之后，他们决定终止这一项目。这将造成约 57 亿丹麦克朗（8.2 亿美元）的减值损失（impairment loss）。之所以做出这一决定，是因为独立监督委员会认为ocedurenone未能达到 12 周后改变血压的主要目标。 Clarion-CKD 是一项针对 600 多名患者的临床项目，研究ocedurenone对高血压失控和晚期慢性肾病患者的作用。该试验未达到其主要终点，即从基线到第 12 周收缩压的变化。去年10 月在宣布这项购买交易时，诺和诺德高管曾表示，他们预测ocedurenone将满足心脏病和慢性肾病患者的巨大需求。诺和诺德在做出终止Clarion-CKD研究之后表示，目前他们正在重新评估ocedurenone针对其它适应症的研究计划。 02 晚期慢性肾病和难治性高血压晚期慢性肾病（CKD）患者的疾病负担很重，并伴有严重的合并症，最常见的是高血压。控制高血压对于这些患者来说至关重要，可以降低相关的发病率和死亡率，以及降低心肾风险，但由于使用现有药物存在安全问题，治疗选择有限。较轻的 CKD 可能多年都无法确诊，而治疗则集中在更明显的高血压、糖尿病和其他合并症问题上。对于那些未患晚期 CKD 的难治性高血压患者来说，螺内酯（spironolactone，商品名Aldactone）比 β 受体阻滞剂（β-blockers，例如Acebutolol，Nadolol，Propranolol等）和 α 受体阻滞剂（α-blockers，例如Cardura，Minipress等）能更有效地降低血压。然而，服用螺内酯会给患者带来安全风险。然后就是依普利酮（Eplerenone），每天服用两次，虽然安全，但降压效果比螺内酯弱得多。患者选择非常有限。高血压领域已经有 15-20 年没有新药了。醛固酮合酶抑制剂baxdrostat公布的II期数据令人鼓舞，但对象是正常肾脏人群。此外，双重内皮素受体拮抗剂aprocitentan也是一个有力竞争者。它在 3 期 PRECISION 试验中针对难治性高血压患者表现出非常好的降压效果，但有水肿副作用，这是内皮素受体拮抗剂常见的副作用。 03 OcedurenoneⅢ期临床失败是该领域的一大遗憾 Ocedurenone为一款非甾体类、第三代盐皮质激素受体拮抗剂（MRA）。醛固酮（aldosterone）激素在高血压过程中扮演着重要的角色，尤其是在肾源性高血压中特别突出。醛固酮是一种由肾上腺皮质分泌的激素，它主要作用于肾脏内的盐皮质激素受体，调节钠钾的代谢来维持体内的电解质平衡。它的主要生理作用包括促进肾小管对钠的重吸收，同时增加钾和氢离子的排泄。在肾小管的集合管和近曲小管，醛固酮促进钠的再吸收，这导致血容量增加，从而使血压升高。醛固酮可以增强肾素-血管紧张素系统（RAAS）的活性。RAAS的激活会导致血管收缩和钠水潴留，进一步提高血压。在高血压患者中，醛固酮的水平通常升高，尤其是在原发性高血压（特别是肾性高血压）和部分难治性高血压患者中。长期高血压导致肾脏血管损伤，进而刺激醛固酮的释放。同时血压升高导致RAAS系统过度活跃，促使醛固酮的合成和释放增加。醛固酮释放不当升高会导致高血压、心血管和肾脏终末器官损伤和衰竭，因此针对这种病理的药物开发主要集中在两个方向：抑制醛固酮合成，以及阻断盐皮质激素受体 (MR)，醛固酮是MR的内源性配体。常见类固醇类MRA（盐皮质激素受体拮抗剂）可以抑制醛固酮与MR受体的作用，可以降低“醛固酮逃逸”，但其应用受到高钾血症的风险而被限制。另外，由于现有类固醇MRA药物对糖皮质激素受体和雄激素受体有作用，导致多种内分泌的不良事件，同样限制了此类药物的广泛应用。以ocedurenone为代表的第三代非甾体类盐皮质激素受体拮抗剂（Non-steroidal mineralocorticoid receptor antagonists，nsMRA）被FDA认定为一种独特的新型抗高血压药物，也成为了治疗CKD和难治性高血压的新希望。Ocedurenone与甾体类MRA截然不同，特点是半衰期长（约为 60 小时），盐皮质激素受体 (MR) 亲和力高，而对糖皮质激素、孕酮和雄激素受体的结合亲和力很小或为零。它不会进入大脑，没有活性代谢物。非甾体 MRA 药物esaxerenone（图2）已在日本获批用于治疗高血压，但其对晚期 CKD 患者的疗效尚未经过测试。拜耳的nsMRA药物finerenone在2021年获得了FDA的批准，用于降低 2 型糖尿病（T2D）相关慢性肾病（CKD）成人患者持续 eGFR （估算肾小球滤过率）下降、肾衰竭、心血管死亡、非致命性心肌梗死（MI）和心力衰竭住院的风险，成为获得FDA批准的首例nsMRA类药物，可显著减缓慢性肾病进展并降低 2 型糖尿病相关慢性肾病患者的心血管风险。图2. nsMRA拮抗剂药物esaxerenone和finerenone化学结构。虽然两款nsMRA被不同的监管机构批准上市，但患有难治性高血压的晚期CKD仍然缺乏有效的治疗方法。Ocedurenone原本肩负着人们攻克这一顽症的希望，而且也收获了令人鼓舞的II期临床数据，但最终的III期临床却没有能够达到设定的血压临床终点，这不得不说是一个相当大的遗憾。参考资料： [1] Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss. Novo Nordisk Press Release. 26. 06. 2024. [2] Kresge, N. Novo to Buy Experimental Heart Drug for Up to $1.3 Billion. Bloomberg. 16. 10. 2023. [3] FDA Approves Kerendia. Drugs.com. July. 2021. [4] Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease. European Medical Journal. 16. 03. 2023. 共建Biomedical创新生态圈！如何加入BiG会员？

临床3期临床终止临床2期临床失败并购

2024-03-07

·BioSpace

CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference

Drug Combination’s Unique Mechanism of Action Enables Reactivation of Brain Adrenergic Function, Showing Improvements in Multiple Areas of Cognition SAN CARLOS, Calif. & LISBON, Portugal--(BUSINESS WIRE)-- CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a data with its combination adrenergic activator, CST-2032/CST-107, in patients with mild cognitive impairment (MCI) or mild dementia from either Alzheimer’s or Parkinson’s disease. The oral presentation will take place at AD/PD™ 2024: The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held March 5-9, 2024, in Lisbon, Portugal. CST-2032 is one of CuraSen’s two lead product candidates being tested in patients with Alzheimer’s and Parkinson’s disease. Both CST-2032 and CST-103, the company’s other lead clinical candidate, are oral, brain-permeant, beta2 adrenoceptor (β2-AR) agonists delivered in combination with CST-107 (nadolol, a brain-sparing beta blocker) to inhibit peripheral effects of β2-AR agonism. Both CST-2032 and CST-103 work by enabling reactivation of brain adrenergic function lost early in the neurodegenerative disease process. The updated Phase 2a data with CST-2032/CST-107 showed statistically and clinically important effects across several cognitive domains in patients with Alzheimer’s and Parkinson’s disease, such as memory, attention, executive function, facial recognition and impulse control — areas known to be impacted by adrenergic function. Target effect sizes of 0.2-0.3 or higher, as seen in this study, predict success in larger, longer studies. “These encouraging data build on earlier results presented at October 2023’s CTAD conference, reinforcing that treatment with CST 2032/CST-107 can produce meaningful quality-of-life cognitive improvements for Alzheimer’s and Parkinson’s patients, particularly those with mild cognitive impairment, rapidly and safely,” said Anthony Ford, PhD, chief executive officer of CuraSen. “The robust, collective data set from both CST-2032 and CST-103 demonstrate that this novel mechanism of action for restoring adrenergic function to the brain is a highly compelling strategy to address unmet symptoms of neurodegeneration. We plan to evaluate additional doses and refine optimal patient profiles in our upcoming Phase 2 studies, with the goal to significantly increase cognitive performance and ultimately, halt disease progression.” The randomized, placebo-controlled, double-blinded crossover study evaluated 64 patients with MCI or mild dementia from either Alzheimer’s disease or Parkinson’s diseases: AD with MCI = 30 patients randomized; 25 completed AD with dementia = 6 patients randomized; 5 completed PD with MCI = 22 patients randomized; 21 completed PD with dementia = 6 patients randomized; 4 completed Data highlights included: Digit Symbol Substitution test, which measures complex attention, memory and executive function: AD patients with MCI = 0.36 effect size; p=0.02 on Day 14 Facial Expression Recognition response time to accurately recognize facial expressions, which measures social cognition: AD patients with MCI = 0.66 effect size; p=0.04 on Day 14 for happy expression and 0.91 effect size; p = 0.01 on Day 14 for surprise expression Stop Signal test, which measures impulse control PD patients with MCI = 0.52 effect size; p=0.04 on Day 14 Excellent safety and tolerability pro /> No serious adverse events: no increases in heart rate observed one to four hours after dose The company plans to initiate longer studies with both CST-2032/CST-107 and CST-103/CST-107 in AD and PD patients with MCI later this year, as well as develop fixed-dose combination tablets for each of these drug candidates. Study Objectives and Design The study objectives were to establish safety and tolerability of CST-2032/CST-107, identify optimal dosing, and identify cognitive tests responsive to agonist stimulus within the two-week dosing period. Measures of cognition included the digit symbol substitution test, Cambridge neuropsychological test battery, and the facial expression recognition task. The study took place at multiple sites in the United States and New Zealand. Patients received either daily 3 mg of CST-2032 with 3 mg of nadolol for 14 days, or matching placebo, followed by a wash-out period (≥7-d) before crossing over to the other treatment arm. Blood samples are being analyzed for AD biomarkers, and DNA samples for AD and PD genotyping. Abstract Details Title: “CST-2032, a Novel Beta-2 Adrenoceptor Agonist, Improves Cognition in Patients with Impairment Due to Alzheimer’s or Parkinson’s Disease” Abstract #: PO34 Presenter: Gabriel Vargas, MD, PhD, chief medical officer, CuraSen Therapeutics Session: Translational Drug Discovery and Experimental Models 05 Date: Saturday, March 9, 2024 Time: 17:25-17:40 UTC, session time,16:40 - 18:40 UTC Location: Auditorium VII About CuraSen Therapeutics CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and other related orphan conditions. CuraSen’s drugs are designed to activate certain receptor populations in the brain to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration and represent a unique approach in the field. The company is evaluating CST-103 and CST-2032, both selective β2-AR agonists, in combination with CST-107, a β-AR blocker, in multiple Phase 2 clinical studies. CST-3056, an α1A-AR agonist, is in preclinical development for the treatment of Alzheimer’s disease. For more information, please visit .

临床2期临床结果

100 项与纳多洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00432	纳多洛尔	C07AA12	DB01203

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
原发性高血压	日本	Sumitomo Pharma Co., Ltd.	1985-08-22
心动过速	日本	Sumitomo Pharma Co., Ltd.	1985-08-22
心绞痛	美国	MDD US Operations LLC	1979-12-10
心动过缓	美国	MDD US Operations LLC	1979-12-10
高血压	美国	MDD US Operations LLC	1979-12-10
甲状腺功能亢进症	美国	MDD US Operations LLC	1979-12-10
偏头痛	美国	MDD US Operations LLC	1979-12-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性咳嗽	临床2期	美国	Invion Ltd.	2014-03-01
慢性阻塞性肺疾病	临床2期	美国	Invion Ltd.	2014-03-01
戒烟	临床2期	美国	Invion Ltd.	2014-03-01
轻度持续性哮喘	临床2期	美国	Invion Ltd.	2013-03-01
胸痛	临床1期	-	山德士有限公司	1994-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02505971 (Pubmed \| JAMA Pediatr) 人工标引	临床3期	毛细血管瘤	71	Nadolol	網製齋網艱糧獵糧顧夢(觸糧衊簾構鏇顧積願憲): difference = 10.1 (95% CI, 2.9 ~ 17.4) 更多	优效	2021-11-08
				Propranolol
NCT01825122 (CTgov)	临床2期	慢性阻塞性肺疾病 \| 戒烟 \| 慢性咳嗽	155	Placebo (Placebo)	網艱餘獵鑰糧艱壓餘襯(壓製餘積襯鏇繭製衊鹹) = 憲獵鹽鏇艱廠醖構淵構餘鏇鬱鏇製築窪製蓋襯 (構鬱鏇範鑰繭糧築艱鹹, 夢艱簾繭獵壓壓積艱窪 ~ 餘襯壓製蓋網夢網壓餘) 更多	-	2016-10-25
				Nadolol (Active, Nadolol)	網艱餘獵鑰糧艱壓餘襯(壓製餘積襯鏇繭製衊鹹) = 鬱艱積繭範廠壓鬱衊蓋餘鏇鬱鏇製築窪製蓋襯 (構鬱鏇範鑰繭糧築艱鹹, 襯網鹽襯鬱願窪壓憲鬱 ~ 廠壓淵夢廠築醖淵衊鬱) 更多
NCT00670267 (CTgov)	临床1/2期	哮喘	10	nadolol	鬱顧壓襯蓋夢構窪鬱製(築艱餘醖積襯襯鹹願繭) = 構顧獵構蓋鹽積廠窪鹹範淵鑰餘鏇餘積築鑰簾 (夢鹽壓製醖襯蓋觸鏇選, 選製鏇繭夢鹽鬱蓋襯糧 ~ 齋壓艱選築簾蓋蓋觸膚) 更多	-	2016-05-11
ISRCTN26221020 (Pubmed \| Gut)	临床2期	出血	158	Nadolol+Isosorbide-5-mononitrate alone	膚襯選製觸製餘構餘繭(齋鑰鑰鑰鏇構艱窪糧觸) = Overall adverse events or those requiring hospital admission were significantly more frequent in the Drug+EBL group 選製構鑰窪醖願襯獵艱 (積願夢構醖範鑰構獵糧 )	-	2009-08-01
				Nadolol+Isosorbide-5-mononitrate + EBL